Application | Comment | Organism |
---|---|---|
drug development | NS3 protease represents a drug target for treatment of HCV infections | Hepatitis C virus genotype 2a |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
BILN-2061 | a NS3 serine protease inhibitor | Hepatitis C virus genotype 2a |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Hepatitis C virus genotype 2a | Q99IB8 | HCV, isolate JFH-1 | - |
Source Tissue | Comment | Organism | Textmining |
---|
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
additional information | NS3 acts as a serine protease and helicase | Hepatitis C virus genotype 2a | ? | - |
? |
Synonyms | Comment | Organism |
---|---|---|
NS3 | - |
Hepatitis C virus genotype 2a |
NS3 serine protease | - |
Hepatitis C virus genotype 2a |
General Information | Comment | Organism |
---|---|---|
malfunction | treatment of virus-infected cells with NS3 enzyme inhibitor BILN-2061 significantly increases degranulation against K-562 target cells and IFN-gamma productivity in natural killer (NK) cells of the host. The expression levels of activating NK cell receptors, such as NKp46 and NKp30, are also increased | Hepatitis C virus genotype 2a |
physiological function | hepatitis C virus impairs natural killer cell activity via viral serine protease NS3. The modulation of natural killer (NK) cell functions by HCV leads to an impaired innate immune response. In HCV-infected Huh-7.5 cells, the serine protease NS3 may play a role in the abrogation of NK cell functions in the early phase of infection through downregulation of NKp46 and NKp30 receptors on NK cells. HCV-NS replicon and HCV-NS3-transfected Huh-7.5 cells attenuate NK cell functions, overview | Hepatitis C virus genotype 2a |